What is the average price target for 4D Pharma PLC (LBPS) stock?
6 analysts have analysed LBPS and the average price target is 7.52 null. This implies a price increase of 356.04% is expected in the next year compared to the current price of 1.65.
4D Pharma PLC (LBPS) Forecast, Price Target & Analyst Ratings
NASDAQ:LBPS • US35085K1097
Current stock price
1.65
+0.04 (+2.48%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for 4D Pharma PLC (LBPS).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
$7.52
Upside
+ 356.04%
From current price of $1.65 to mean target of $7.52, Based on 6 analyst forecasts
Low
$7.45
Median
$7.52
High
$7.75
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
6 Wall Street analysts provided a forecast for the next 12 months for LBPS. The average price target is 7.52 null. This implies a price increase of 356.04% is expected in the next year compared to the current price of 1.65.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
LBPS was analyzed by 6 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about LBPS.
In the previous month the buy percentage consensus was at a similar level.
LBPS was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-06-27 | Chardan Capital | Downgrade | Buy -> Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Sep 28, 2022
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 210K | 530K 152.38% | 520K -1.89% | 16.362M 3,046.54% | 17.01M 3.96% | 17.861M 5.00% | N/A | N/A | |
| EBITDA YoY % growth | -29.36M -5.20% | -29.34M 0.07% | -25.54M 12.95% | -24.24M 5.09% | -26.26M -8.33% | -28.381M -8.08% | -25.794M 9.11% | -23.678M 8.21% | |
| EBIT YoY % growth | -30.64M -5.22% | -30.54M 0.33% | -26.52M 13.16% | -17.17M 35.26% | -21.419M -24.75% | -26.986M -25.99% | N/A | N/A | |
| Operating Margin | -14,590.48% | -5,762.26% | -5,100.00% | -104.94% | -125.92% | -151.09% | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A 29.90% | -1.18 -7.11% | -1.35 -14.89% | -1.54 -13.50% | -1.30 15.05% | -1.12 14.20% |
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-11.78%
EPS Next 5 Year
-0.36%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
4D Pharma PLC / LBPS Forecast FAQ
Can you provide the upcoming earnings date for 4D Pharma PLC?
4D Pharma PLC (LBPS) will report earnings on 2022-09-28.
What is the consensus rating for LBPS stock?
The consensus rating for 4D Pharma PLC (LBPS) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.